Incyte Corporation
RUXOLITINIB FORMULATION FOR REDUCTION OF ITCH IN ATOPIC DERMATITIS

Last updated:

Abstract:

This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Status:
Application
Type:

Utility

Filling date:

28 Mar 2022

Issue date:

8 Sep 2022